# Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

> **NCT04343651** · PHASE2 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Coronavirus Disease 2019

## Interventions

- **DRUG:** Placebo
- **DRUG:** Leronlimab (700mg)

## Key facts

- **NCT ID:** NCT04343651
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-01
- **Primary completion:** 2020-07-21
- **Final completion:** 2021-09-20
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343651, "Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04343651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*